Date	Period	Revenue/Estimate	Earnings Call
--	2024/Q4	-- / 81.163B	--
--	2024/Q3	-- / 71.998B	--
Aug 7, 2024	2024/Q2	68.060B / 68.563B	--
May 2, 2024	2024/Q1	65.349B / 63.573B	--
Jan 31, 2024	2023/Q4	65.863B / 61.207B	--

DatePeriodRevenue/EstimateEarnings Call

--2024/Q4-- / 81.163B--

--2024/Q3-- / 71.998B--

Aug 7, 20242024/Q268.060B / 68.563B--

May 2, 20242024/Q165.349B / 63.573B--

Jan 31, 20242023/Q465.863B / 61.207B

Novo Nordisk Q4 2023 earnings conference call

Jan 31 06:00

Unlock Free Earnings Estimates

Open Account

6-K: Financial Report for the Period 1 January 2024 to 30 June 2024

Aug 7 06:56 ET

6-K: Novo Nordisk Stops the Ocedurenone CLARION-CKD Trial and Recognises Impairment Loss

Jun 26 13:22 ET

6-K: Financial Report for the Period 1 January 2024 to 31 March 2024

May 2 07:18 ET

Novo-Nordisk A/S | 6-K: Report of foreign private issuer (related to financial reporting)

Jan 31 07:03 ET

Updated: Oct 14, 2024

Strong Buy

No Data

Overall

No Data

NVO Novo-Nordisk A/S

Novo-Nordisk A/S Key Stats